The Native Antigen Company, the Oxford-based company which last year sold for £18 million to Middlesex-headquartered life sciences company LGC, has launched its SARS-CoV-2 Neutralisation Assay Development Kit.
The kit can be used to identify and assess the ability of antibodies to neutralise SARS-CoV-2-receptor binding, to support research into variants and their effects on natural and vaccine-induced patient immunity.
Dr Andy Lane, Commercial Director, The Native Antigen Company, said: “This marks The Native Antigen Company’s first release of a dedicated kit for the development of neutralisation assays [tests]. Our data demonstrates the SARS-CoV-2 Neutralisation Assay Development Kit’s effectiveness and we are confident in its ability to support vital research and development efforts for public health.”
The Native Antigen Company is now part of LGC Clinical Diagnostics and one of the world’s leading suppliers of reagents that enables research into diagnostics and vaccines for emerging and endemic infectious diseases.
The easy-to-use kit contains all the key reagents required to measure SARS-CoV-2-antibody binding, including the Spike receptor-binding domain (RBD) of the prototypic Wuhan-Hu-1 strain, labelled ACE2, and positive and negative monoclonal antibody controls. These reagents enable the assessment of neutralising activity of patient and therapeutic antibodies, and can be used alongside The Native Antigen Company’s growing range of SARS-CoV-2 variant Spike proteins to assess differences in antibody/ACE2 affinities and competitive binding.
The Native Antigen Company’s in-house data shows that COVID-19 patient sera is able to effectively neutralise the RBD and prevent it from binding to the human ACE2 cell surface receptor.